Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma: A Phase 2 Trial in the North Central Cancer Treatment Group

BACKGROUND: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL). METHODS: Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg int...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ansell, Stephen M., Inwards, David J., Rowland, Kendrith M., Flynn, Patrick J., Morton, Roscoe F., Moore, Dennis F., Kaufmann, Scott H., Ghobrial, Irene, Kurtin, Paul J., Maurer, Matthew, Allmer, Christine, Witzig, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627208/
https://ncbi.nlm.nih.gov/pubmed/18543327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23580
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados